share_log

T2 Biosystems | 4: Statement of changes in beneficial ownership of securities-10% Owner CR Group L.P.

T2 Biosystems | 4: Statement of changes in beneficial ownership of securities-10% Owner CR Group L.P.

T2 Biosystems | 4：持股变动声明-股东 CR Group L.P.
美股sec公告 ·  04/16 20:41
Moomoo AI 已提取核心信息
CR Group L.P., a significant stakeholder in T2 Biosystems, Inc. [TTOO], reported a series of acquisitions of common stock on April 12, 2024. The transactions were made through various entities associated with CR Group L.P. and were all indirect acquisitions. A total of 682,036 shares were acquired by CRG Partners III L.P., 424,716 shares by CRG Partners III - Parallel Fund (A) L.P., 136,409 shares by CRG Partners III (Cayman) Unlev AIV I L.P., 1,647,315 shares by CRG Partners III (Cayman) Lev AIV I L.P., and 390,142 shares by CRG Partners III - Parallel Fund B (Cayman) L.P. These acquisitions significantly increased CR Group L.P.'s holdings in T2 Biosystems, with the total number of shares held after the transactions amounting to 4,104,838. The nature of the shares is indirect, and the transactions are classified as grants, awards, or other acquisitions.
CR Group L.P., a significant stakeholder in T2 Biosystems, Inc. [TTOO], reported a series of acquisitions of common stock on April 12, 2024. The transactions were made through various entities associated with CR Group L.P. and were all indirect acquisitions. A total of 682,036 shares were acquired by CRG Partners III L.P., 424,716 shares by CRG Partners III - Parallel Fund (A) L.P., 136,409 shares by CRG Partners III (Cayman) Unlev AIV I L.P., 1,647,315 shares by CRG Partners III (Cayman) Lev AIV I L.P., and 390,142 shares by CRG Partners III - Parallel Fund B (Cayman) L.P. These acquisitions significantly increased CR Group L.P.'s holdings in T2 Biosystems, with the total number of shares held after the transactions amounting to 4,104,838. The nature of the shares is indirect, and the transactions are classified as grants, awards, or other acquisitions.
T2 Biosystems, Inc. [TTOO] 的重要利益相关者CR集团有限责任公司于2024年4月12日报告了一系列普通股收购。这些交易是通过与CR Group L.P. 相关的多个实体进行的，均为间接收购。CRG Partners III L.P. 共收购了682,036股股票，CRG Partners III——平行基金（A）有限责任公司共收购了424,716股股票，CRG Partners III L.P. 收购了136,409股股票，CRG Partners III L.P. 收购了1,647,315股股票，CRG Partners III L.P. 收购了1,647,315股...展开全部
T2 Biosystems, Inc. [TTOO] 的重要利益相关者CR集团有限责任公司于2024年4月12日报告了一系列普通股收购。这些交易是通过与CR Group L.P. 相关的多个实体进行的，均为间接收购。CRG Partners III L.P. 共收购了682,036股股票，CRG Partners III——平行基金（A）有限责任公司共收购了424,716股股票，CRG Partners III L.P. 收购了136,409股股票，CRG Partners III L.P. 收购了1,647,315股股票，CRG Partners III L.P. 收购了1,647,315股股票，CRG Partners III L.P. 收购了390,142股股票-Parallel Fund B（开曼）L.P. 这些收购极大地增加了CR Group L.P.持有T2 Biosystems的股份，交易后持有的股份总数为4,104,838股。股份的性质是间接的，交易被归类为赠款、奖励或其他收购。

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息